These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25303159)

  • 1. Bone morphogenetic protein-associated complications in pediatric spinal fusion in the early postoperative period: an analysis of 4658 patients and review of the literature.
    Rocque BG; Kelly MP; Miller JH; Li Y; Anderson PA
    J Neurosurg Pediatr; 2014 Dec; 14(6):635-43. PubMed ID: 25303159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population-based review of bone morphogenetic protein: associated complication and reoperation rates after lumbar spinal fusion.
    Savage JW; Kelly MP; Ellison SA; Anderson PA
    Neurosurg Focus; 2015 Oct; 39(4):E13. PubMed ID: 26424337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nationwide practice patterns in the use of recombinant human bone morphogenetic protein-2 in pediatric spine surgery as a function of patient-, hospital-, and procedure-related factors.
    Lam SK; Sayama C; Harris DA; Briceño V; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2014 Nov; 14(5):476-85. PubMed ID: 25171721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of bone morphogenetic protein in thoracolumbar spine procedures: analysis of the MarketScan longitudinal database.
    Veeravagu A; Cole TS; Jiang B; Ratliff JK; Gidwani RA
    Spine J; 2014 Dec; 14(12):2929-37. PubMed ID: 24842396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does bone morphogenetic protein increase the incidence of perioperative complications in spinal fusion? A comparison of 55,862 cases of spinal fusion with and without bone morphogenetic protein.
    Williams BJ; Smith JS; Fu KM; Hamilton DK; Polly DW; Ames CP; Berven SH; Perra JH; Knapp DR; McCarthy RE; Shaffrey CI;
    Spine (Phila Pa 1976); 2011 Sep; 36(20):1685-91. PubMed ID: 21897187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory meta-analysis on dose-related efficacy and morbidity of bone morphogenetic protein in spinal arthrodesis surgery.
    Hofstetter CP; Hofer AS; Levi AD
    J Neurosurg Spine; 2016 Mar; 24(3):457-75. PubMed ID: 26613283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of routine use of recombinant human bone morphogenetic protein-2 in occipitocervical and atlantoaxial fusions of the pediatric spine: a minimum of 12 months' follow-up with computed tomography.
    Sayama C; Hadley C; Monaco GN; Sen A; Brayton A; Briceño V; Tran BH; Ryan SL; Luerssen TG; Fulkerson D; Jea A
    J Neurosurg Pediatr; 2015 Jul; 16(1):14-20. PubMed ID: 25860982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reoperation rates for symptomatic nonunions in posterior cervical (subaxial) fusions with and without bone morphogenetic protein in a cohort of 1158 patients.
    Guppy KH; Harris J; Chen J; Paxton EW; Alvarez J; Bernbeck J
    J Neurosurg Spine; 2016 Apr; 24(4):556-64. PubMed ID: 26722955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spinal fusion for pediatric neuromuscular scoliosis: national trends, complications, and in-hospital outcomes.
    Rumalla K; Yarbrough CK; Pugely AJ; Koester L; Dorward IG
    J Neurosurg Spine; 2016 Oct; 25(4):500-508. PubMed ID: 27203810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures.
    Cahill KS; Chi JH; Day A; Claus EB
    JAMA; 2009 Jul; 302(1):58-66. PubMed ID: 19567440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of bone morphogenetic protein among patients undergoing fusion for degenerative diagnoses in the United States, 2002 to 2012.
    Martin BI; Lurie JD; Tosteson AN; Deyo RA; Farrokhi FR; Mirza SK
    Spine J; 2015 Apr; 15(4):692-9. PubMed ID: 25523380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological trends in the utilization of bone morphogenetic protein in spinal fusions from 2002 to 2011.
    Singh K; Nandyala SV; Marquez-Lara A; Fineberg SJ
    Spine (Phila Pa 1976); 2014 Mar; 39(6):491-6. PubMed ID: 24365905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label use of bone morphogenetic proteins in the United States using administrative data.
    Ong KL; Villarraga ML; Lau E; Carreon LY; Kurtz SM; Glassman SD
    Spine (Phila Pa 1976); 2010 Sep; 35(19):1794-800. PubMed ID: 20700081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone morphogenetic protein use in spine surgery in the United States: how have we responded to the warnings?
    Guzman JZ; Merrill RK; Kim JS; Overley SC; Dowdell JE; Somani S; Hecht AC; Cho SK; Qureshi SA
    Spine J; 2017 Sep; 17(9):1247-1254. PubMed ID: 28456674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications, revision fusions, readmissions, and utilization over a 1-year period after bone morphogenetic protein use during primary cervical spine fusions.
    Goode AP; Richardson WJ; Schectman RM; Carey TS
    Spine J; 2014 Sep; 14(9):2051-9. PubMed ID: 24321129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reoperation rates for symptomatic nonunions in posterior cervicothoracic fusions with and without bone morphogenetic protein in a cohort of 450 patients.
    Guppy KH; Harris J; Chen J; Paxton EW; Bernbeck JA
    J Neurosurg Spine; 2016 Sep; 25(3):309-17. PubMed ID: 27104284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of transforaminal lumbar interbody fusion outcomes in patients receiving rhBMP-2 versus autograft.
    Khan TR; Pearce KR; McAnany SJ; Peters CM; Gupta MC; Zebala LP
    Spine J; 2018 Mar; 18(3):439-446. PubMed ID: 28822825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications associated with recombinant human bone morphogenetic protein use in pediatric craniocervical arthrodesis.
    Lindley TE; Dahdaleh NS; Menezes AH; Abode-Iyamah KO
    J Neurosurg Pediatr; 2011 May; 7(5):468-74. PubMed ID: 21529186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reoperation Rates After Long Posterior Spinal Fusion: Use of Recombinant Bone Morphogenetic Protein in Idiopathic and Non-idiopathic Scoliosis.
    Paul JC; Lonner BS; Vira S; Kaye ID; Errico TJ
    Spine Deform; 2016 Jul; 4(4):304-309. PubMed ID: 27927521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usage of recombinant human bone morphogenetic protein in cervical spine procedures: analysis of the MarketScan longitudinal database.
    Cole T; Veeravagu A; Jiang B; Ratliff JK
    J Bone Joint Surg Am; 2014 Sep; 96(17):1409-16. PubMed ID: 25187578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.